|
1
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: European Organisation for Research and Treatment of
Cancer Brain Tumor and Radiotherapy Groups; National Cancer
Institute of Canada Clinical Trials Group: Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N Engl J
Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cuddapah VA, Robel S, Watkins S and
Sontheimer H: A neurocentric perspective on glioma invasion. Nat
Rev Neurosci. 15:455–465. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nieder C, Grosu AL, Astner S and Molls M:
Treatment of unresectable glioblastoma multiforme. Anticancer Res.
25(6C): 4605–4610. 2005.PubMed/NCBI
|
|
6
|
Stupp R, Pavlidis N and Jelic S: ESMO
Guidelines Task Force: ESMO Minimum Clinical Recommendations for
diagnosis, treatment and follow-up of malignant glioma. Ann Oncol.
16:(Suppl 1). i64–i65. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huse JT and Holland EC: Targeting brain
cancer: Advances in the molecular pathology of malignant glioma and
medulloblastoma. Nat Rev Cancer. 10:319–331. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Epstein AC, Gleadle JM, McNeill LA,
Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI,
Dhanda A, et al: C. elegans EGL-9 and mammalian homologs define a
family of dioxygenases that regulate HIF by prolyl hydroxylation.
Cell. 107:43–54. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ivan M, Haberberger T, Gervasi DC,
Michelson KS, Günzler V, Kondo K, Yang H, Sorokina I, Conaway RC,
Conaway JW and Kaelin WG Jr: Biochemical purification and
pharmacological inhibition of a mammalian prolyl hydroxylase acting
on hypoxia-inducible factor. Proc Natl Acad Sci USA.
99:13459–13464. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kivirikko KI and Myllyharju J: Prolyl
4-hydroxylases and their protein disulfide isomerase subunit.
Matrix Biol. 16:357–368. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bruick RK and McKnight SL: A conserved
family of prolyl-4-hydroxylases that modify HIF. Science.
294:1337–1340. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McNeill LA, Hewitson KS, Gleadle JM,
Horsfall LE, Oldham NJ, Maxwell PH, Pugh CW, Ratcliffe PJ and
Schofield CJ: The use of dioxygen by HIF prolyl hydroxylase (PHD1).
Bioorg Med Chem Lett. 12:1547–1550. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Maxwell PH, Wiesener MS, Chang G-W,
Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER and
Ratcliffe PJ: The tumour suppressor protein VHL targets
hypoxia-inducible factors for oxygen-dependent proteolysis. Nature.
399:271–275. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ivan M, Kondo K, Yang H, Kim W, Valiando
J, Ohh M, Salic A, Asara JM, Lane WS and Kaelin WG Jr: HIFalpha
targeted for VHL-mediated destruction by proline hydroxylation:
Implications for O2 sensing. Science. 292:464–468. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gordan JD and Simon MC: Hypoxia-inducible
factors: Central regulators of the tumor phenotype. Curr Opin Genet
Dev. 17:71–77. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Keith B and Simon MC: Hypoxia-inducible
factors, stem cells, and cancer. Cell. 129:465–472. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kaelin WG Jr: The von Hippel-Lindau tumour
suppressor protein: O2 sensing and cancer. Nat Rev
Cancer. 8:865–873. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Semenza GL: Angiogenesis in ischemic and
neoplastic disorders. Annu Rev Med. 54:17–28. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Appelhoff RJ, Tian Y-M, Raval RR, Turley
H, Harris AL, Pugh CW, Ratcliffe PJ and Gleadle JM: Differential
function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the
regulation of hypoxia-inducible factor. J Biol Chem.
279:38458–38465. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rankin EB, Rha J, Unger TL, Wu CH, Shutt
HP, Johnson RS, Simon MC, Keith B and Haase VH: Hypoxia-inducible
factor-2 regulates vascular tumorigenesis in mice. Oncogene.
27:5354–5358. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ryan HE, Lo J and Johnson RS: HIF-1 alpha
is required for solid tumor formation and embryonic
vascularization. EMBO J. 17:3005–3015. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lipscomb EA, Sarmiere PD, Crowder RJ and
Freeman RS: Expression of the SM-20 gene promotes death in nerve
growth factor-dependent sympathetic neurons. J Neurochem.
73:429–432. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chan DA, Kawahara TL, Sutphin PD, Chang
HY, Chi JT and Giaccia AJ: Tumor vasculature is regulated by
PHD2-mediated angiogenesis and bone marrow-derived cell
recruitment. Cancer Cell. 15:527–538. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chan DA and Giaccia AJ: PHD2 in tumour
angiogenesis. Br J Cancer. 103:1–5. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Erez N, Milyavsky M, Eilam R, Shats I,
Goldfinger N and Rotter V: Expression of prolyl-hydroxylase-1
(PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation
and inhibits tumor growth. Cancer Res. 63:8777–8783.
2003.PubMed/NCBI
|
|
26
|
Hatzimichael E, Dasoula A, Shah R, Syed N,
PapoudouBai A, Coley HM, Dranitsaris G, Bourantas KL, Stebbing J
and Crook T: The prolyl-hydroxylase EGLN3 and not EGLN1 is
inactivated by methylation in plasma cell neoplasia. Eur J
Haematol. 84:47–51. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Henze AT, Riedel J, Diem T, Wenner J,
Flamme I, Pouyseggur J, Plate KH and Acker T: Prolyl hydroxylases 2
and 3 act in gliomas as protective negative feedback regulators of
hypoxia-inducible factors. Cancer Res. 70:357–366. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mazzone M, Dettori D, de Oliveira R Leite,
Loges S, Schmidt T, Jonckx B, Tian YM, Lanahan AA, Pollard P, de
Almodovar C Ruiz, et al: Heterozygous deficiency of PHD2 restores
tumor oxygenation and inhibits metastasis via endothelial
normalization. Cell. 136:839–851. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Z, Bao S, Wu Q, Wang H, Eyler C,
Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, et al:
Hypoxia-inducible factors regulate tumorigenic capacity of glioma
stem cells. Cancer Cell. 15:501–513. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hamidouche Z, Haÿ E, Vaudin P, Charbord P,
Schüle R, Marie PJ and Fromigué O: FHL2 mediates
dexamethasone-induced mesenchymal cell differentiation into
osteoblasts by activating Wnt/β-catenin signaling-dependent Runx2
expression. FASEB J. 22:3813–3822. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fulda S and Pervaiz S: Apoptosis signaling
in cancer stem cells. Int J Biochem Cell Biol. 42:31–38. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Su Y, Loos M, Giese N, Hines OJ, Diebold
I, Görlach A, Metzen E, Pastorekova S, Friess H and Büchler P: PHD3
regulates differentiation, tumour growth and angiogenesis in
pancreatic cancer. Br J Cancer. 103:1571–1579. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kovalenko A, ChableBessia C, Cantarella G,
Israël A, Wallach D and Courtois G: The tumour suppressor CYLD
negatively regulates NF-kappaB signalling by deubiquitination.
Nature. 424:801–805. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jaakkola P, Mole DR, Tian Y-M, Wilson MI,
Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji
M, Schofield CJ, et al: Targeting of HIF-alpha to the von
Hippel-Lindau ubiquitylation complex by O2-regulated
prolyl hydroxylation. Science. 292:468–472. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xie L, Xiao K, Whalen EJ, Forrester MT,
Freeman RS, Fong G, Gygi SP, Lefkowitz RJ and Stamler JS:
Oxygen-regulated β(2)-adrenergic receptor hydroxylation by EGLN3
and ubiquitylation by pVHL. Sci Signal. 2:ra332009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Luo W, Hu H, Chang R, Zhong J, Knabel M,
O'Meally R, Cole RN, Pandey A and Semenza GL: Pyruvate kinase M2 is
a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell.
145:732–744. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xue J, Li X, Jiao S, Wei Y, Wu G and Fang
J: Prolyl hydroxylase-3 is down-regulated in colorectal cancer
cells and inhibits IKKbeta independent of hydroxylase activity.
Gastroenterology. 138:606–615. 2010. View Article : Google Scholar : PubMed/NCBI
|
